research compound comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-13. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Alexander Butlerov showed in 1861 that the formose reaction created sugars including tetroses, pentoses, and hexoses when formaldehyde is heated under basic conditions with divalent metal ions like calcium. R. Breslow proposed that the reaction was autocatalytic in 1959.
== Epidemiology == Cardiovascular disease, which is predominantly the clinical manifestation of atherosclerosis, is one of the leading causes of death worldwide. Almost all children older than age 10 in developed countries have aortic fatty streaks, with coronary fatty streaks beginning in adolescence. In 1953, a study was published that examined the results of 300 autopsies performed on U.S. soldiers who had died in the Korean War. Despite the average age of the soldiers being just 22 years old, 77% of them had visible signs of coronary atherosclerosis. This study showed that heart disease could affect people at a younger age and was not just a problem for older individuals. In 1992, a report showed that microscopic fatty streaks were found in the left anterior descending artery in over 50% of children aged 10–14, and 8% had even more advanced lesions with more accumulations of extracellular lipid. A 2005 report of a study from 1985 to 1995 found that around 87% of aortas and 30% of coronary arteries in the age group 5–14 years had fatty streaks, which increased with age.
Langer's lines, Langer lines of skin tension, or sometimes called cleavage lines, are topological skin lines drawn on a map of the human body. They are parallel to the natural orientation of collagen fibers in the dermis, and generally parallel to the underlying muscle fibers. Langer's lines have relevance to forensic science and the development of surgical techniques.
Sources: en.wikipedia.org
Liu had seized the Chengdu Arsenal in 1925 after Yang Sen's downfall, but to appease the city's other warlords, he announced plans to convert it into a mechanical repair shop rather than a weapons factory. To oversee this process, he appointed his brother Liu Wencheng, who had previously run a distillery, as its manager. Liu Wencheng would also later be appointed to several managerial positions in industrial enterprises. The Chengdu Arsenal would eventually be converted into a mint, increasing Liu Wenhui's money supply. Liu's brother Wencheng used his position in Chengdu to purchase houses and land, expanding his family's real estate holdings. He purchased so much property that his rivals nicknamed him "Liu Half-City", implying he owned half of Chengdu. Liu Wenhui's army continued growing due to money and industrial supplies from his brothers. Over the course of 1926, he attacked and disarmed the forces of Yang Chunfang in January and Lü Chao in April, taking control of Lü's territories in southern Sichuan. To formalize the division of Chengdu, Liu, Deng, and Tian established a joint command in December 1926 with Liu as director. In December 1926, communist forces under Liu Bocheng launched the Luzhou Uprising in Sichuan as part of the Northern Expedition. Liu Bocheng's forces successfully took control of the city from warlord Lai Xinhui. Control of Luzhou was coveted by several neighboring warlords, who had also begun besieging the city. To prevent his rivals from capturing Luzhou, Liu dispatched his friend Leng Yingdong to surround the city in April 1927.
In 2012, the American Academy of Dermatology published appropriate use criteria (AUC) on Mohs micrographic surgery in collaboration with the following organizations: American College of Mohs Surgery; American Society for Mohs Surgery; and the American Society for Dermatologic Surgery Association. More than 75 physicians contributed to the development of the Mohs surgery AUC, which were published in the Journal of the American Academy of Dermatology and Dermatologic Surgery. The Australasian College of Dermatologists, in concert with the Australian Mohs Surgery Committee, has also developed evidence based guidelines for Mohs Surgery. The Mohs procedure is a pathology sectioning method that allows for the complete examination of the surgical margin. It is different from the standard bread loafing technique of sectioning, where random samples of the surgical margin are examined. Mohs surgery is performed in four steps:
=== 1990 === January 13, 1990 – The Stasi, the secret police of East Germany, is dissolved. January 22, 1990 – the League of Communists of Yugoslavia, the ruling party of the Socialist Federal Republic of Yugoslavia, is dissolved during its congress, ending the one party system in the country. February 1, 1990 – StB, the secret police of Czechoslovakia is dissolved. March 15, 1990 – Inauguration of Gorbachev as the first president of the Soviet Union. April 12, 1990 – The Socialist Republic of Slovenia within Yugoslavia holds its first multi-party elections. April 22–23 and May 6–7, 1990 – the Socialist Republic of Croatia within Yugoslavia holds its first multi-party elections. April 25, 1990 – Violeta Chamorro is sworn in as president of Nicaragua, ending the Sandinista rule and the Contras insurgency. May 22, 1990 – South and North Yemens are unified. June 8, 1990 – the Message from Turnberry, described as the "first official recognition of the end of the Cold War", is issued. July 5–6, 1990 – NATO holds its 11th summit in London. July 13, 1990 – The 28th Congress of the Communist Party of the Soviet Union announces the end of its monopoly of power. August 2, 1990 – Beginning of Gulf War. September 9, 1990 – Helsinki Summit between Bush and Gorbachev. September 12, 1990 – The Treaty on the Final Settlement with Respect to Germany is signed in Moscow. October 3, 1990 – Official reunification of Germany. November 6, 1990 – Hungary become the first Soviet Bloc country to join the Council of Europe.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.